Jefferies Sets a $28 PT for enGene Holdings Inc. (ENGN)
We recently published an article titled 10 Best Low Volatility Canadian Stocks to Buy.
On January 30, Jefferies initiated coverage of enGene Holdings Inc. (NASDAQ:ENGN) with a Buy rating and a $28 price target, highlighting the company’s ongoing pivotal study in high-risk non-muscle invasive bladder cancer (NMIBC), with a key data update expected in the second half of 2026.
enGene Holdings Inc. (NASDAQ:ENGN) is positioning itself as a differentiated player in the bladder cancer treatment landscape as it advances detalimogene voraplasmid, its lead non-viral gene therapy candidate, into late-stage development. Beyond clinical momentum, enGene has strengthened its financial footing. On January 21, the company expanded its debt facility with Hercules Capital to up to $125 million, securing additional non-dilutive financing to support its planned Biologics License Application and potential U.S. commercialization. The amended agreement provides $25 million immediately to refinance existing debt and up to $100 million in additional tranches tied to clinical, regulatory, and commercial milestones. This capital structure enhances flexibility as enGene transitions from a development-stage biotech to a potential commercial-stage company in a competitive but high-need oncology market.
Founded in 1999 and headquartered in Saint-Laurent, Quebec, enGene Holdings Inc. (NASDAQ:ENGN) leverages its proprietary Dually Derivatized Chitosan (DDX) platform to develop non-viral genetic medicines targeting mucosal diseases. With pivotal data on the horizon, strengthened liquidity, and a differentiated therapeutic approach, enGene represents a high-risk, high-reward opportunity for investors seeking exposure to innovative oncology platforms with meaningful upside potential.
Disclosure: None.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Gold recovers from YTD low, retakes $3,900; Fed hike bets and bullish USD to cap gains
Cerebras (CBRS.US) Cloud Business Soars, Masking Hardware Decline; OpenAI Supports Half of Cloud Revenue
Cerebras achieved record Q3 revenue, but hardware income dropped by nearly 30%, while cloud business accounted for two-thirds of total revenue. OpenAI contributed $72.4 million. The company raised its full-year guidance and expects Q4 to be close to breakeven.
Microsoft (MSFT.US) offers voluntary buyout packages to about 60,000 employees: Structural divergence in U.S. employment under AI transformation
In 2026, the U.S. labor market is characterized by both low layoffs and weak hiring. Companies like Microsoft and American Express are leveraging AI to optimize their workforce, while data centers are driving growth in the construction sector. However, entry-level white-collar jobs face increasing pressure, with real wages experiencing negative growth and structural transformation risks becoming more prominent.
Crypto prices
More
